Investment Thesis
Grace Therapeutics is unprofitable with -$7.8M net loss and negative operating cash flow of -$8.9M, indicating the company cannot convert $100M in revenue into positive operating results despite 18.6% YoY net income improvement. With only $17M cash and an ~$9M annual burn rate, the company has approximately 2 years of runway before requiring profitability or additional capital. While the strong balance sheet and improving loss trajectory are positives, the fundamental inability to generate operating cash flow presents an unacceptable risk profile.
Strengths
- Strong balance sheet with $63.9M stockholders' equity, only $2.8M liabilities, and zero long-term debt providing substantial financial cushion
- Excellent liquidity position with 8.1x current ratio and $17M in cash equivalents
- Rapidly improving loss profile with net income up 18.6% YoY and diluted EPS up 40.5% YoY demonstrating directional momentum toward profitability
Risks
- Significant operating cash burn of -$8.9M annually despite positive revenue, indicating fundamental operational inefficiency and questionable revenue quality
- Limited cash runway of approximately 2 years at current burn rate creates near-term capital adequacy risk requiring either profitability achievement or dilutive financing
- Missing gross profit data and undefined revenue growth trajectory (N/A YoY) prevent full assessment of business model viability and operational leverage potential
Key Metrics to Watch
- Operating cash flow conversion - must achieve positive OCF to validate path to sustainability
- Gross margin and operating expense ratio trends - determines whether improving losses translate to long-term profitability
- Cash burn rate deceleration - critical indicator of timeline to profitability versus need for capital raise
Financial Metrics
Revenue
100.0M
Net Income
-7.8M
EPS (Diluted)
$-0.47
Free Cash Flow
-8.9M
Total Assets
66.7M
Cash
17.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-11.1%
Net Margin
-7.8%
ROE
-12.2%
ROA
-11.7%
FCF Margin
-8.9%
Balance Sheet & Liquidity
Current Ratio
8.10x
Quick Ratio
8.09x
Debt/Equity
0.00x
Debt/Assets
4.1%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-07-29T06:06:37.416415 |
Data as of: 2026-03-31 |
Powered by Claude AI